Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Results reported from phase III BLOOM-DM weight loss study in type 2 diabetes

Nov. 9, 2010

Ardea Biosciences reports data on RDEA-594 in gout

Nov. 9, 2010

Phase IIb data reported on LIPO-102 for selective nonablative fat reduction

Nov. 8, 2010

FDA approves once-daily Kombiglyze XR tablets for type 2 diabetes

Nov. 8, 2010

Swedish Orphan Biovitrum sells back copromotion rights for Mimpara to Amgen

Nov. 5, 2010

Ortho-McNeil-Janssen ends collaboration with Arena Pharma for APD-597 program

Nov. 5, 2010

Kowa claims new erythropoietin production enhancers

Nov. 5, 2010

Primary endpoint met in phase III HPN-100 trial in urea cycle disorders

Nov. 4, 2010

ENB-0040 shows promise to treat hypophosphatasia in children

Nov. 4, 2010

New neuropeptide Y5 receptor antagonists discovered

Nov. 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...